Neurophysiology of erection and ejaculation

F Giuliano - The journal of sexual medicine, 2011 - Elsevier
Introduction Penile erection and ejaculation are closely associated during sexual
intercourse. Erection is a central psychoneuroendocrine and peripheral neuro-vasculo …

Non-invasive management options for erectile dysfunction when a phosphodiesterase type 5 inhibitor fails

M Lee, R Sharifi - Drugs & aging, 2018 - Springer
Phosphodiesterase type 5 inhibitors (PDE5Is) are the drug of choice for medical
management of erectile dysfunction (ED). On-demand PDE5Is have an overall efficacy of 60 …

Ligand‐Promoted meta‐C−H Functionalization of Benzylamines

P Wang, ME Farmer, JQ Yu - Angewandte Chemie, 2017 - Wiley Online Library
Meta‐C− H functionalization of benzylamines has been developed using a PdII/transient
mediator strategy. Using 2‐pyridone ligands and 2‐carbomethoxynorbornene (NBE …

Tri-Substituted Triazole-Enabled C–H Activation of Benzyl and Aryl Amines by Iron Catalysis

Z Shen, G Cera, T Haven, L Ackermann - Organic letters, 2017 - ACS Publications
The design of trisubstituted triazoles set the stage for proximity-induced iron-catalyzed C–H
activation of benzyl and aryl amines with ample scope. Thereby, C–H alkylations and C–H …

Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats

Y Bai, R An - Life sciences, 2015 - Elsevier
Aims Despite effective control of blood glucose levels in diabetic patients, complaints of
diabetes-associated erectile dysfunction (ED) persist. Resveratrol has been indicated to …

A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or …

E Rubio-Aurioles, H Porst, ED Kim… - The Journal of …, 2012 - academic.oup.com
ABSTRACT Aim To compare Sexual Self-Confidence and other treatment outcomes
following 8 weeks of treatment with tadalafil 5 mg once a day (OaD) vs. tadalafil 20 mg or …

Stem cells in male sexual dysfunction: are we getting somewhere?

MA Soebadi, U Milenkovic, E Weyne… - Sexual medicine …, 2017 - academic.oup.com
Introduction Stem cells for sexual disorders are steadily being introduced into clinical trials.
Two conditions of importance are the main target for this line of treatment, especially when …

[HTML][HTML] Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction

M Bieri, E Said, G Antonini, D Dickerson… - Journal of translational …, 2020 - Springer
Background Bone marrow mononuclear cells have been successfully utilized for numerous
regenerative purposes. In the current study, patients suffering from erectile dysfunction (ED) …

Phase I and phase II clinical trials for the treatment of male sexual dysfunction—a systematic review of the literature

P Capogrosso, F Montorsi, A Salonia - Expert Opinion on …, 2018 - Taylor & Francis
Introduction: The prevalence of sexual dysfunctions has increased over the last decades;
despite a number of available treatments for erectile dysfunction (ED), premature ejaculation …

Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor …

L Luo, DZ Dai, YS Cheng, Q Zhang… - Journal of Pharmacy …, 2011 - academic.oup.com
Objectives Abnormal vascular activity in diabetes is related not only to impaired nitric oxide
bioavailability but also to inflammatory cytokines, endothelin A receptor (ETA) activation and …